23 August 2014 in Molecular Carcinogenesis
25 February 2011 in The Prostate
1 September 2006 in Rejuvenation Research
Given the constitutive expression of telomerase in the majority of human tumors, telomerase inhibition is an attractive, broad-spectrum therapeutic target for cancer treatment. Therapeutic strategies for inhibiting telomerase activity have included both targeting components of telomerase (the protein component, TERT, or the RNA component, TERC) or by directly targeting telomere DNA structures. Recently a combination telomerase inhibition therapy has been studied also. The TERT promoter has been used to selectively express cytotoxic gene(s) in cancer cells and a TERT vaccine for immunization against telomerase has been tested. The 10% to 15% of immortalized cancer cells that do not express telomerase use a recombinationbased mechanism for maintaining telomere structures that has been called the alternative lengthening of telomeres (ALT). In view of the increasing study of telomerase inhibitors as anticancer treatments, it will be crucial to determine whether inhibition of telomerase will select for cancer cells that activate ALT mechanisms of telomere maintenance.
1 January 2007 in Cancer Investigation
The Akt kinase is a serine/threonine protein kinase that has been implicated in mediating a variety of biological responses, is associated with a poor pathophenotype in breast carcinoma, and is involved in hormone and chemotherapy resistance, including resistance to the antiestrogen, tamoxifen. Akt promotes cell survival by phosphorylating and inactivating proapoptotic proteins and increasing the transcription of survival genes. To explore the role that specific components of the Akt kinase pathway play in the cellular response to tamoxifen, we transfected MCF-7 cells with an expression plasmid for a constitutively active Akt. We found that MCF-7 breast cancer cell lines expressing a constitutively active Akt are able to proliferate under reduced estrogen conditions and are resistant to the growth inhibitory effects of tamoxifen, both in vitro as well as in vivo in xenograft models. Initial analysis of the molecular responses in the Akt/MCF-7 xenografts to tamoxifen suggests that high Akt activity alters apoptotic responses to tamoxifen. Control MCF-7 xenografts demonstrated activation of the proapoptotic forkhead (FKHR) transcription factor in response to tamoxifen treatment, while the xenografts expressing the constitutively active Akt transgene demonstrated no alterations in FKHR expression. In addition, TUNEL analysis demonstrated higher levels of apoptosis in the control xenografts in response to tamoxifen treatment compared to the Akt xenografts. Inhibition of Akt activity in vitro restored apoptotic responses to tamoxifen in the Akt/MCF-7 cells to those observed in the control cells. These data suggest that alteration of survival responses is an important mechanism by which Akt confers resistance to tamoxifen.
6 November 2017 in Neuro-Oncology
Meningioma account for 36% of intracranial tumors and 4.7-7.2% demonstrate aggressive clinical behavior. Current treatments are limited to surgery and radiation. We investigated hypoxia activated prodrugTH302 in patient-derived xenograft model of malignant meningioma. Female athymic nude mice were implanted subcutaneously with human meningioma tissue obtained intraoperatively. After 80 days of tumors growth animals were randomized into four groups 1) Control(n=1), 2) XRT (n=4), 3) TH302(n=5), and 4) XRT+TH302(n=4). Mice were either focally radiated using LINAC system in five fractions of 3Gy given daily to a total of 15 Gy, treated with TH302 at 50mg/kg started on day 3 of radiation for 9 doses every other day or combination of both. Tumor volume was measured by a digital caliper until endpoint of 4000 mm3 was reached. H&E, IHC and western blot analysis were performed to further elucidate mechanism of action in meningioma. Additionally, CH157MN meningioma cell line is being used for drug concentration screening (0.1uM - 500uM) to determine IC50 under normaxia and hypoxia conditions using MTT assay. Tumor growth in 1)Control: 1199 mm3 to 4371 mm3 in 35 days, 2)XRT: 890 mm3 to 4220 mm3 in 91 days, 3)TH302: 660 mm3 to 4894 mm3 in 130 days and 4)XRT+TH302: 890 mm3 to 4266 mm3 in 155 days. FFPE H&E and CA9 stained sections show increase in necrotic regions while decrease in hypoxia in XRT/TH302 vs XRT. Western blot showed increase in Chk1, Rad51, and Polβ in XRT+TH302. Our in vivo study shows that mice treated with XRT+TH302 compared to XRT alone have prolonged survival with p<0.0206 with decreased rate of tumor growth likely from TH302-dependent DNA damage of hypoxic cells resulting in cell death.